// App-Quantinova.ai

2583 : Correlation of an Aurora A single nucleotide polymorphism (SNP) with clinical responses to alisertib in patients (pts) with advanced solid tumors.

Researchers

Presenter

  • Huifeng Niu

Principal Investigators

  • Hyunjin Shin

  • Feng Gao

  • Jacob Zhang

  • Brittany Bahamon

  • Hadi Danaee

  • Bohuslav Melichar

  • Russell J. Schilder

  • Robert L. Coleman

  • Antoine Adenis

  • Kian Behbakht

  • Angela DeMichele

  • Elizabeth Claire Dees

  • Kimberly Perez

  • Ursula A. Matulonis

  • Dirk Huebner

  • Jeffrey Ecsedy

Medical Centers

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Palacky University Medical School & Teaching Hospital, Olomouc, Czech Republic

  • Thomas Jefferson University, Philadelphia, PA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Centre Oscar Lambret, Lille, France

  • University of Colorado Denver School of Medicine, Aurora, CO

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • University of North Carolina, Chapel Hill, NC

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

  • Czech Republic

  • France

Companies

  • Millennium Pharmaceu

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Ovarian cancer

Biomarkers

  • N/A

Drug/Treatment

  • Paclitaxel

  • Alisertib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT01045421

  • NCT01091428

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved